All In Biotech

Drug Trial Radar · NCT04023019

Treatment of Hemophilia A Patients With FVIII Inhibitors

MOdern Treatment of Inhibitor-PositiVe PATiEnts With Haemophilia A - An International Observational Study

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Mar 17, 2020

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Octapharma
First posted
Jul 17, 2019

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-interventional, multicenter, observational, international study in male persons with haemophilia A who have developed inhibitors to any replacement coagulation factor VIII (FVIII) product. The purpose of the study is to capture different approaches in the management of persons with haemophilia A and FVIII inhibitors, document current immune tolerance induction approaches, and evaluate the efficacy and safety of immune tolerance induction, including the combination of FVIII and emicizumab. Patients will be assigned to 1 of 3 groups based on the treatments they receive, and may switch to another group if their treatment is changed. Participants will be followed after a maximum observational period of 5 years.

Conditions

  • Hemophilia A

Interventions

  • NuwiqBiological

    Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

  • OctanateBiological

    Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

  • WilateBiological

    Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

  • EmicizumabBiological

    Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

  • Recombinant factor VIIa (rFVIIa)Biological

    Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

  • Activated prothrombin complex concentrate (aPCC)Biological

    Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving inhibitor titer < 0.6 Bethesda units (BU)/mL L for at least 2 consecutive measurementsTime frame: Up to 5 years
  2. Proportion of participants achieving FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg body weight (Groups 1 and 2)Time frame: Up to 5 years
  3. Proportion of participants achieving FVIII half-life ≥ 6 h (Groups 1 and 2)Time frame: Up to 5 years
  4. Annualized bleeding rateTime frame: Up to 5 years

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Arthur M. Blank Hospital

    Atlanta, Georgia · Recruiting

  • HZRM Hämophilie-Zentrum Rhein Main

    Mörfelden-Walldorf, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.